Perspectives · Consolidation

The Companion Trade

For a decade the veterinary roll-up ran on three tailwinds: abundant capital, one-way demand, and a pricing lever no one was watching. In the eighteen months to mid-2026 all three turned at once. What the second act actually rewards.

Corryk · June 2026

In brief

The consolidation of European veterinary care is treated as finished business, and in one sense it is: the model that built the platforms has stopped working. It ran on three tailwinds — capital that was cheap, demand that only rose, and a price no regulator was watching — and in the eighteen months to the middle of 2026 all three have turned. The instructive thing for anyone still allocating to the sector is not that the roll-up happened; it is what the reversal now selects for. The scarce input has moved from capital, which was never really scarce, to the one thing a balance sheet cannot manufacture: delivered clinical hours. This note is for readers who know the first act and are underwriting the second.

What has turned

Capital. Early in 2026 the largest, most heavily levered platform pulled a ~$5.5bn refinancing for want of demand and was downgraded; a listed, lightly levered peer, by contrast, refinanced tighter and bought back stock. The cost of leverage now sorts the field.

Price. The UK regulator’s final verdict landed in March 2026 — comparison sites, ownership disclosure, prescription-fee caps — and France’s authority has opened the same file. The pricing opacity that let the pass-through work is being removed, market by market.

Demand. The pandemic pet bulge has deflated below its pre-2020 level, visit volumes are softening and cost-of-living is pushing owners to defer care. Humanisation is intact; the one-way growth is not.

1 · Capital: the spread has closed

The engine of the trade was never operational genius; it was an arbitrage. Buy an owner-run clinic at five or six times earnings, fold it into a platform the market valued at fourteen to sixteen, and the re-rating did the work before a single synergy landed. That spread has compressed by roughly a third from its 2021 peak, and the compression is no longer a forecast — it is showing up in the financing markets.

The clearest signal came this winter, in the financing markets rather than the clinics. On leveraged-finance reporting, the largest platform in Europe — some 2,600 clinics across roughly twenty countries, sponsor-owned and assembled on leverage — withdrew a roughly five-and-a-half-billion-dollar refinancing for want of investor appetite, and carried a ratings downgrade into the spring; its filed accounts show tens of millions spent on the regulatory probe alone. In the same window a listed, lightly levered peer refinanced its facilities tighter, stepped up to a larger index, and launched a buyback. Two businesses in the same industry, pulling in opposite directions, separated by one variable: how much debt was used to assemble them. The cheap-capital era did not just end; it began to sort the survivors from the over-levered.

Two businesses in the same industry, pulling in opposite directions, separated by one variable: how much debt was used to assemble them.

2 · Price: the opacity is being removed

The second tailwind was a price nobody was auditing. That ended in March 2026, when the UK Competition and Markets Authority closed a two-year investigation with a finding an insider could have sketched but few had seen quantified: veterinary prices had risen sixty-three per cent between 2016 and 2023, roughly twice general inflation, and the cause was not margin expansion but pay — bid up in the corporate hiring war and passed straight to the customer. It put five-year consumer detriment at £1.7 billion. The remedies matter less for what they cap than for what they reveal: comparable price lists, an online comparison tool, disclosure of the group behind the local name, written estimates, and a cap on prescription fees. They do not cap service prices — but transparency, not a price control, is what disarms an arbitrage that depended on the customer not being able to compare.

Read the finding against the remedy and the mechanism breaks. The arbitrage’s middle step — absorb an independent, lift its prices, re-rate the earnings — is precisely what the transparency package is built to prevent. Note the counter-intuitive sting the incumbents were quick to point out: real-time price publication and e-prescribing are compliance burdens an independent bears less easily than a platform, so the rules meant to protect the small operator may accelerate the very consolidation they targeted — even as advisers warn the majors may now divest portfolios bought at the top.

The CMA remedies, March 2026

Comparable price lists and an RCVS-run price-comparison service; compulsory disclosure of large-group ownership; written estimates above £500; a cap on prescription fees (£21 first item, £12.50 per additional); and a duty to flag that medicines are cheaper online. Phased into force from September 2026 through 2027–28. Only prescription fees are capped — the rest force transparency; none caps service prices, and none touches the wage bill.

These are the remedies the CMA has ordered. They should not be confused with the separate government track: on 9 July 2026 Defra published a reform White Paper (CP 1615) proposing a licence to practise, statutory regulation of veterinary businesses, protection of the nurse title and an independent ombudsman — proposals, not yet law, and a second front of change the sector must now underwrite.

Nor is it one jurisdiction. In October 2025 France’s competition authority published its opinion on veterinary pricing (Avis 25-A-12), flagging the corporate build-up as a structural risk to prices and documenting that five groups already control over seventy per cent of veterinary-medicine purchasing. Corporate networks’ share of French clinics has, on trade estimates, climbed toward a third from a low base. The UK verdict is a template other regulators are now holding up to their own markets.

3 · Demand: the bulge has deflated

The third tailwind is the one the sector talks about least, because it undercuts the story everyone tells about pets as recession-proof family members. The humanisation is real and durable. The growth was not one-way; a large slice of it was a pandemic bulge, and the bulge has burst. UK pedigree-dog registrations — a leading, if partial, proxy for the flow of new animals — have fallen by more than a third from their 2021 peak to below where they sat in 2019.

What follows the bulge is worse for a volume model than a simple plateau. The 2020–21 cohort is ageing out of its high-spend puppy years while a share of it is surrendered by the young, cost-pressed owners who took it on; shelter intake is up and regret is rising. Cost-of-living is now visible in the consulting room: on the veterinary charity’s data, some three million UK pets have had care deferred, and the share of owners not registering a pet at all because of cost has climbed. The hard visit-volume series is American — US visits down about three per cent in 2025, new clients down nearly nine — but the direction is not in doubt, and pet-care market forecasts have quietly reset from high-single-digit growth to something nearer four per cent. A discretionary, cash-pay service meets a squeezed consumer just as the regulator makes its prices comparable.

Where that squeeze bites is not uniform, and the map that predicts it is the insurance map. Where pets are insured, demand is buffered and price-inelastic; where they are not, it is cash and exposed the moment prices are made comparable. Outside the Nordics, Europe is overwhelmingly cash-pay — France around five per cent of pets insured, Germany about two once you strip out the dog-liability cover routinely miscounted as health. The Nordic markets that look most consolidated are the best insulated from a transparency shock; the Continental markets that look least developed on insurance are the most exposed.

4 · The operational turn: labour decides the survivors

Strip out the three tailwinds and what is left is an operating business whose binding constraint is people. This is where the workforce story matters — not as the crisis that justified paying up, which is receding, but as the thing that now separates operators who can run what they bought from those who merely bought it. The regulator’s own model has the small-animal shortage essentially closing by 2035; the catch is that it closes on headcount, and headcount is not what a practice sells.

Delivered capacity is decoupling from the register. On the same projection, full-time-equivalent hours grow markedly slower than the number of names, and average FTE per vet slips from 0.85 toward 0.79 — so a model that prices capacity off registrant counts already overstates it by about a sixth, widening every year. The driver is slow to reverse: the profession has feminised, women are twice as likely to work part-time, and part-time working has climbed from a fifth of the profession to better than a quarter.

Two 2026 developments bear directly on who can manage this. First, the wage spiral that the CMA blamed for the price rises has broken: the latest salary survey has average vet pay up just over two per cent, well below veterinary cost inflation — relief on the largest cost line, but a sign of a cooling market, not a generous one. Second, and more consequential, the one genuine lever for throughput — delegating clinical work to nurses — is being widened exactly where it already exists. Britain has a protected, registered veterinary-nurse profession, and the government’s July 2026 reform White Paper proposes to protect the title further, regulate the practising business, and expand the nurse’s scope. Most of the Continent has no registered nurse role at all, and so lacks the capacity valve entirely; Continental throughput stays bottlenecked on a workforce with fewer full-time hours behind each registrant, and no nurse valve to relieve it.

Exhibit 8 · The delegation lever: where veterinary nurses add capacity

A protected nurse role expands the work a veterinary practice can safely delegate; where it is absent, clinician capacity remains the bottleneck.

For readers inclined to be bearish on operators: in the pan-European survey, corporate-owned practices reported no more burnout leave than independents, and the largest reported the least. The capacity problem is structural, not a morale story — which means it is an operating problem a good operator can out-execute.

5 · Where the value is now

If the returns no longer come from the multiple or the price, they come from two places: buying well, and running well. Buying well, in this market, means sourcing from the demographic wave rather than bidding for trophy platforms. The seller pipeline is not a cycle to be timed; it is a retirement schedule that can be read years ahead from the age profile of registered owners — three thousand-plus in Germany alone this decade — and it is deepest on a Continent where consolidation has barely started.

Running well means putting capacity where demand still outruns it. Even with the bulge deflating, humanisation keeps the veterinary hours per animal high against a supply that is flattening, and the load is heaviest where vets are thinnest.

Overlay the two and origination sorts itself. The value sits upper-left — markets with many animals, relatively few vets, still fragmented, and ideally with enough insurance to blunt the transparency shock. The trap sits lower-right and, more dangerously, in the markets that look most “proven”: labour-tight, already consolidated, bought at a peak multiple that the next buyer will not pay.

6 · What the deal tables miss

A word on seeing this from the outside, because much of it is invisible in the league tables. A large share of operator changes never appears in a deal database at all: a practice is de-registered and re-registered at the same address under a new owner, with no announcement. Tracking those changes through the registers rather than the press shows a consolidation rate higher than the reported count — and shows the cycle plainly. It crested with the cost of capital in 2021–22 and has cooled since.

It also shows the cast, and the cast is short. A handful of backed platforms account for most recorded operator changes, market after market — and it is that same handful whose second act will now be judged not on what it can still buy but on how it runs what it already owns.

7 · The bottom line

The companion trade’s first act was financial, and it worked because three things were true at once: money was free, demand only climbed, and no one was checking the prices. By the middle of 2026 none of the three holds. The capital markets are sorting the levered from the disciplined; the regulators, plural, are capping the price; and the demand curve has bent. What remains is a genuinely good end-market — humanised, cash-generative, still fragmented across most of Europe — that now has to be operated rather than merely assembled.

The scarce input is no longer capital. On the evidence of 2026, it never was — it just took a credit cycle, two regulators and a deflating bulge to make the labour visible.

The second act rewards a narrower skill than the first: sourcing from the succession wave rather than bidding for platforms, converting headcount into delivered hours through nurse leverage where the law allows it, and routing capital to the undersupplied, still-independent, insured catchments where demand outruns supply. It punishes the opposite — a peak multiple in a labour-tight market, mistaken for a proven one. That distinction does not show up in a deal table. It shows up in the workforce, and in the cost of the debt.

— Corryk

Comments, corrections or questions on this article: perspectives@corryk.com.